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stages of the disease, indications of a more pronounced dis-
turbance of visuospatial abilities as compared to face and 
object recognition. Non-cognitive symptoms most often in-
cluded myoclonus and cerebellar ataxia. A review of the 
available case reports indicates some phenotypic variability 
associated with the S170F mutation including different con-
stellations of symptoms such as parkinsonism and delusions. 
Conclusion: The variable clinical findings associated with 
the S170F mutation highlight the relevance of atypical phe-
notypes in the context of research and under a clinical per-
spective. CSF sampling and detection of Aβ species may be 
essential to indicate AD pathology in unclear cases present-
ing with cognitive and motor symptoms at a younger age.
© 2018 S. Karger AG, Basel
Introduction
A very small proportion of Alzheimer disease (AD) 
patients presents with an early onset of dementia (before 
65 years of age) and a suggestive familial pattern with sev-
eral other affected first-degree relatives in 2 or more gen-
erations indicating an autosomal dominant mode of in-
heritance [1, 2]. Three causative genes for such early-on-
set familial Alzheimer dementia (EOFAD) have been 
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Abstract
Background: In rare cases, patients with Alzheimer disease 
(AD) present at an early age and with a family history sugges-
tive of an autosomal dominant mode of inheritance. Muta-
tions of the presenilin-1 (PSEN1) gene are the most common 
causes of dementia in these patients. Early-onset and par-
ticularly familial AD patients frequently present with variable 
non-amnestic cognitive symptoms such as visual, language 
or behavioural changes as well as non-cognitive, e.g. motor, 
symptoms. Objective: To investigate the phenotypic vari-
ability in carriers of the PSEN1 S170F mutation. Methods: We 
report a family with 4 patients carrying the S170F mutation 
of whom 2 underwent detailed clinical examinations. We 
discuss our current findings in the context of previously re-
ported S170F cases. Results: The clinical phenotype was 
consistent regarding initial memory impairment and early 
onset in the late twenties found in all S170F patients. There 
were frequent non-amnestic cognitive changes and, at early 
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identified: presenilin-1 (PSEN1) on chromosome 14 and 
its homologue presenilin-2 (PSEN2) on chromosome 1 as 
well as amyloid-β (Aβ) precursor protein (APP) on chro-
mosome 21 [1]. So far, the Alzheimer Disease & Fronto-
temporal Dementia Mutation Database [3] (http://www.
molgen.vib-ua.be/ADMutations) comprises 286 muta-
tions of PSEN1, PSEN2, and APP in 635 affected individ-
uals or families. Most frequent are mutations of PSEN11 
(n = 219, 76.6%) as compared to APP (n = 51, 17.8%), and 
PSEN2 (n = 16, 5.6%) [4–6]. PSEN1 codes for the trans-
membrane protein presenilin-1 which assembles with co-
factors nicastrin, Aph-1 and Pen-2 to form the 4 subunits 
of the γ-secretase complex [7, 8]. Pathogenic mutations 
of PSEN1 have been found to alter the cleavage of APP by 
the γ-secretase complex [9], increasing the production of 
Aβ fragments associated with the deposition of amyloid 
plaques, most notably Aβ42 but also other Aβ isoforms 
[10, 11]. These findings have been interpreted in support 
of the amyloid cascade hypothesis stating that accumula-
tion of Aβ is the primary event in AD pathophysiology 
which eventually leads to tau-mediated neurodegenera-
tion and cognitive decline [12].
Investigations in asymptomatic PSEN1 mutation car-
riers have demonstrated that first changes of cerebrospi-
nal fluid (CSF) biomarkers and positron emission tomog-
raphy using Pittsburgh compound B tracer indicate de-
position of Aβ already decades before the expected onset 
of symptoms [13]. Given the failure of several drug trials 
in clinically affected AD patients, this has emphasized the 
question “when, where, and how” [14] first pathophysi-
ological changes in AD occur and may be therapeutically 
targeted [15]. In this context, observations in familial AD 
cases are generally considered as informative for the gen-
eration and adaptation of hypotheses about AD patho-
physiology and possible treatment strategies [16, 17].
However, some significant differences apart from age 
at onset have also raised the question to what extent one 
can infer from familial to sporadic, late-onset AD [18, 19]. 
For instance, familial and sporadic AD share the neuro-
pathological hallmarks of AD pathology such as deposi-
tion of amyloid plaques and accumulation of neurofibril-
lary tangles [17], but the pathological results in EOFAD 
are more variable and frequently include findings such as 
cotton wool plaques, Lewy bodies, Pick bodies, and pro-
nounced inflammation [20–22]. Likewise, the clinical 
phenotype of PSEN1 mutation carriers is characterized 
by widespread deficits involving multiple cognitive do-
mains [23–25], resembling cognitive changes observed in 
sporadic AD [26], but atypical findings such as early non-
amnestic cognitive, behavioural or motor symptoms are 
observed more frequently [27–34]. There is, however, 
considerable intra- and interfamilial variability regarding 
e.g. the occurrence of such atypical symptoms, age at on-
set, and the course of disease [35–38]. To account for this 
diversity of clinical findings genotype-phenotype correla-
tions can be investigated in larger populations of EOFAD 
patients [25, 32, 39] or single patients in comparison to 
previous descriptions of a given mutation [37, 38]. The 
latter is however complicated due to a bias towards the 
publication of novel mutations whereas the informative 
value of detailed clinical observations in known muta-
tions is underestimated [3, 27–29]. Beyond a research-
oriented perspective, this is also clinically relevant: famil-
ial AD may be overall rare, it is nevertheless underdiag-
nosed in relation to its assumed prevalence [40], and this 
may be attributed to its heterogeneous and atypical clini-
cal presentation.
Against this background, the aim of this article is to 
report a family with overall 4 individuals in 3 generations 
affected by EOFAD due to the S170F2 mutation of PSEN1 
as determined by genetic testing in 2 patients. Observa-
tions in patients harbouring this mutation have been de-
scribed – with considerable differences across reports – in 
consecutive publications since 2005 [41–45]. The most 
consistent findings associated with this mutation are a 
very early onset of dementia in the late twenties and cer-
ebellar ataxia as a prominent non-cognitive symptom 
whereas the degree of variability of genotype-phenotype 
correlations in S170F carriers remains unclear. We will 
discuss the clinical and neuropsychological information 
obtained in our detailed examinations of 2 affected fam-
ily members in the context of these previous reports.
Methods
Two patients consulted the outpatient memory clinic at the 
Department of Neurology of the Charité – Universitätsmedizin. 
Before, both had been seeking genetic counselling where a genet-
ic neurodegenerative disorder had been suspected and genetic 
testing was performed. Simultaneously, both patients were re-
ferred to our department for the required clinical investigations. 
Here, they underwent detailed examinations in the hospital or as 
1
  The frequency of mutations per gene is taken from the Alzheimer Dis-
ease & Frontotemporal Dementia Mutation Database (as of September 
2017).
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outpatients including neuropsychological testing at various points 
in time as well as magnetic resonance imaging (MRI), electro-
encephalography (EEG), and CSF sampling. All diagnostic proce-
dures were performed after the patients had given their informed 
consent and in accordance with current diagnostic guidelines, and 
the study was conducted in accordance with the declaration of 
Helsinki. To maintain anonymity of patients and relatives, we do 
not include a pedigree and limit the report to information relevant 




Both the index patient (III.1) and his sister (III.2) had 
a family history of early-onset dementia in their mother 
and maternal grandmother. The mother of both patients 
(II.1) had developed progressive memory loss approxi-
mately in her late twenties and died from pneumonia by 
the age of 32 after becoming mute and bedridden in an 
advanced stage of dementia. A medical record then had 
noted severe cognitive dysfunction, dysarthria, ataxia, 
dystonic hand movements, and reduced facial expres-
sions. EEG was abnormal showing generalized cerebral 
dysfunction without further specification in the report. A 
computed tomography scan showed massive general cor-
tical atrophy. The maternal grandmother (I.1) of both pa-
tients died by the age of 36 after cognitive decline over few 
years; further information was not available. Taken to-
gether, the family history was highly suggestive of auto-
somal-dominant inheritance with apparently 4 affected 
individuals including first-degree relatives in 3 genera-
tions [2].
Genetic testing at the Institute for Medical Genetics of 
the Charité – Universitätsmedizin Berlin was initially 
done for spinocerebellar ataxia type 17 (SCA17) due to 
ataxia and dementia being the leading symptoms in the 
index patient (III.1), yielding a negative result. There-
upon, sequencing of PSEN1 revealed the S170F muta-
tion, which was later confirmed in his sister (III.2). The 
pathogenic nature of the S170F mutation has been estab-
lished before in several familial as well as sporadic cases 
[41–45].
Clinical Findings
In the following, the signs and symptoms noted in 
both of our patients as well as the results of neuropsycho-
logical examinations are summarized, the testing proce-
dures employed are given in parentheses. An overview 
about the tests and results can be taken from Table 1.
Individual III.1
The index patient III.1 was 31 years old at the time of 
the first clinical examination. Signs of short-term memo-
ry loss, problems of coordination and unsteady gait had 
become apparent during the past 3 years, eventually lead-
ing to genetic counselling and referral to our clinic. He 
was disoriented in time, and neurological examination 
showed limb ataxia, dysmetria and intention tremor, dys-
diadochokinesia, insecure stance and gait, saccadic pur-
suit, slight dysarthria, and spontaneous limb myoclonus. 
A neuropsychological examination showed reduced ver-
bal memory (delayed recall of 1/10 words), impaired at-
tention and task switching (Trail-Making Test, TMT 
A/B). In addition, results of verbal and visuospatial work-
ing memory tests (forward and backward digit span task, 
block-tapping test) were below normal. Verbal fluency 
was also reduced in the phonemic (K words) and seman-
tic (animals) task. The performance in face and object 
recognition tasks (Benton Facial Recognition Test; Bos-
ton Naming Test) was within normal. The result of the 
Clock-Drawing Test (CDT) was also within normal (2 
points, cut-off ≥3), despite obvious difficulties while 
completing the task. The Mini-Mental State Examination 
(MMSE) score was 23/30 (cut-off 26/30).
In 2 follow-up evaluations 6 and 15 months later at the 
age of 32 years, the patient was no longer able to follow 
some test instructions (e.g., TMT) so that the obvious fur-
ther decline of some cognitive functions could not be sub-
stantiated. The available tests showed deterioration of vi-
suoconstruction (CDT: 4 points; Fig. 1), verbal fluency, 
impaired executive functioning (executive interview 
EXIT-25) [46] and visuospatial abilities (computer-based 
assessment of visual functions) [47] such as mental rota-
tion and estimating the positioning of objects. The latter 
must be taken as rather qualitative information because 
the computer-based assessment of visual functions was 
not completed due to problems comprehending the more 
complex test instructions.
Due to the rapid cognitive decline and progressive gait 
disturbance, the patient was referred to a nursing home 
at the age of 32. At 34, the patient was bedridden, tube-
fed, and frequent epileptic seizures were reported, but no 
further follow-up information was available.
Individual III.2
Individual III.2 was referred to our clinic at the age of 
28 after the diagnosis of EOFAD had been established in 
her older half-brother. The patient complained of pro-
gressive memory loss and “clumsiness” over the last year. 

























   
   
   
   
   






















and gait as well as limb ataxia, bilateral pyramidal signs, 
mild dysarthria, and ideomotor apraxia. A first neuropsy-
chological assessment showed impaired verbal (Verbal 
Learning and Memory Test) and non-verbal memory 
(Rey-Osterrieth Complex Figure Test) whereas working 
memory was intact (forward/backward digit span task). 
Tests of attention (TAP alertness), cognitive speed pro-
cessing and task-switching (TMT A/B), executive func-
Table 1. Neuropsychological examinations
Tests Subject III.1 Subject III.2
1 Orientation
MMSE (cut-off ≤26/30) 22 21
2 Visual perception
Clock-Drawing Test (cut-off ≥3) 4 4 
ROCF copy 16 (PR <1)
ROCF immediate recall not able to complete
ROCF delayed recall not able to complete
CERAD figure: immediate copy 9 (PR <2)
CERAD figure: recall 1 (PR <1)
CAV object recognition not able to complete PR >25
CAV visuospatial abilities not able to complete PR <10
Benton facial recognition test (short form) 22 (normal)
Benton facial recognition test (long form) 45 (normal)
3 Attention
TMT A 145 s (PR <1) 105 s (PR <1)
TMT B aborted >300 s aborted >300 s
SKT attention 16 (PR <2) 16 (PR <2)
TAP alertness (no warning cue) 555 ms (PR <1)
TAP alertness (with warning cue) 363 ms (PR <4) with 29 anticipations
4 Memory
Forward digit span task 4 (PR 4) 6 (PR <28)
Backward digit span task 3 (PR 5) 3 (PR <5)
SKT memory 8 (PR <15) 7 (PR <15)
VLMT immediate recall 14 (PR <5)
VLMT recall after interference 0 (PR <5)
VLMT delayed free recall 0 (PR <5)
VLMT recognition 4 (PR <5)
CERAD word list learning 7 (PR <1) 10 (PR <5)
CERAD word list recall 0 (PR <1) 0 (PR <1)
CERAD word list recognition 75% correct (PR <1) 80% correct (PR <1)
5 Executive function and language
EXIT-25 (cut-off >10) 17 13
Verbal fluency, semantic 6 (PR <2) <14 (PR <10)
Verbal fluency, phonemic 2 (PR <2) <7 (PR <10)
Boston Naming Test 54 (PR 31)
If tests were performed repeatedly, results of the latest examinations are shown. Due to the cognitive impair-
ment of both patients, some tests could not be repeated or performed at all; therefore, the applied tests vary in 
both individuals. If applicable, a cut-off value for the respective test is given in parentheses; otherwise, all results 
are given with respect to the percentile rank (PR) of the control groups. PR >25 = unaffected, PR >10 to <25 = 
minor deficits, PR <10 = major deficits. The given numbers are points or scores unless noted otherwise. CAV, 
computer-based assessment of visual functions; CERAD, Consortium to Establish a Registry of Alzheimer’s dis-
ease (battery of neuropsychological tests); EXIT-25, executive interview; MMSE, Minimal Mental Status Exami-
nation; ROCF, Rey-Osterrieth Complex Figure; SKT, Syndrom-Kurz-Test (Syndrome Short Test); TAP, Test of 

























   
   
   
   
   
























tioning (EXIT-25) [46], and visuoconstruction (CDT) 
yielded abnormal results. A subsequent neuropsycholog-
ical assessment 7 months later illustrated further decline 
in working memory tasks (digit span task) and visuocon-
structive functions (Table 1; Fig. 1). Some of the tests pre-
viously conducted could not be performed again due to 
deficits in comprehension of test instructions. Visuospa-
tial abilities such as mental rotation or angle estimation 
(computer-based assessment of visual functions) had also 
deteriorated. Of note, object recognition remained intact. 
Verbal fluency (semantic and phonemic) was markedly 
reduced; the MMSE score was 21/30. Due to rapid pro-
gression of dementia and motor symptoms, the patient 
was living in a nursing home at the time of the last follow-
up at the age of 30 years.
Diagnostic Procedures
Clinical examination included MRI of the brain, EEG 
and blood/CSF sampling yielding altogether similar re-
sults in both patients. MRI revealed cortical atrophy ac-
centuated in the parietal lobes as well as deepened and 
widened cerebellar sulci (Fig.  2). EEG showed diffuse 
slowing of background activity within theta frequency 
(5–6 Hz) with intermittent delta waves over bilateral 
frontal electrodes (III.1), extending to parietal and tem-
poral areas (III.2). Additionally, the EEG of III.2 showed 
generalized spikes whereas epileptiform activity was not 
observed in III.1. CSF samples showed normal routine 
parameters and no oligoclonal bands; Aβ42 was reduced 
(III.1: 444 pg/mL, III.2: 521 pg/ml; normal value >600), 
and levels of total tau protein were markedly increased (in 
both patients >1,200 pg/mL; normal value <225).
Discussion
We report a German family with 4 individuals affected 
by early-onset dementia and presenting with similar phe-
notypes. The PSEN1 S170F mutation was detected by 
DNA sequencing in 2 patients. This mutation results in 
an amino acid change from serine (TCT) to phenylala-
nine (TTT) at codon 170 on exon 6 of the PSEN1 gene 
encoding the transmembrane domain III of presenilin-1, 
where many pathogenic mutations are found to cluster 
[28]. The pathogenic nature of the S170F mutation has 
been established before in several reported familial as well 
as sporadic cases: it was first demonstrated in a North 
American family with 3 affected family members in 2 
generations [44], another family from Austria with 5 cas-
es spanning 3 generations [45] as well as single sporadic 
cases from Great Britain and Poland with de novo muta-
tions [41, 42] and 1 patient in Italy with an incomplete 
family history [43]. Altogether, data from 15 patients (9 
women) with more detailed clinical information in 10 are 
currently available; a comparative summary of findings 
associated with the S170F mutation can be found in Ta-
ble 2.
Fig. 1. Deterioration of visuoconstruction. 
The results of the CDT (left, patient III.1) 
and the Rey-Osterrieth Complex Figure 
Test (right, patient III.2) indicate a rapid 
deterioration of visuoconstructive abilities 
over the course of 6 and 7 months, respec-
tively. The instruction for the CDT was to 
draw a clock showing a time of 11.10 h. The 
right part of the figure shows the direct 
copy of the Rey-Osterrieth Complex Figure 
Test, a delayed recall of the figure was not 
possible. Some lines of the original pencil 
drawings were too faint for scanning and 

























   
   
   
   
   






















Pathogenicity of the PSEN1 S170F Mutation
The S170F mutation is among the highly pathogenic 
PSEN1 mutations with a very early onset as well as rapid 
and severe course of disease in our cases as well as across 
publications. First symptoms are typically observed in the 
late twenties (mean age at onset 29.1 ± 2.3 years, range 
26–34 years). The time from symptom onset until a state 
of dependency was less than 5 years (mean 3.7 ± 1.1 
years), and 10 of the reported patients had died before or 
passed away during observation at a mean age of 35.4 ± 
3.2 years (range 32–43 years), the mean disease duration 
from symptom onset until death being 7.2 ± 4.2 years. 
The majority of PSEN1 mutations is associated with a 
greater range [27], especially when investigations involve 
larger populations of mutation carriers [35, 48], and in 
some cases pedigree-specific age at onset [37]. Carriers of 
the S170F mutation were also affected earlier than pa-
tients included in larger investigations of autosomal-
dominant AD in general (mean age at onset 46.2 years 
[39]) and PSEN1 mutations in particular (mean age at 
onset of 43 years in 3 separate studies [31, 33, 34]). This 
difference is smaller when comparing the S170F cases 
with other PSEN1 mutations also located before codon 
200 (mean age at onset 37.3 years [32]), indicating an in-
teraction between the location of a given mutation and its 
neurotoxicity. The S170F mutation, like most pathogenic 
PSEN1 mutations, is located at one of the transmembrane 
domains of presenilin-1, and in silico modelling suggests 
that it alters interaction between proteins within the 
γ-secretase complex [41]. However, the aggressiveness of 
a given mutation is better reflected by the increase in Aβ42 
levels and the Aβ42/Aβ40 ratio [10, 49], which are inverse-
ly correlated with the age at onset in familial AD [50]. 
With respect to the S170F mutation, in vitro investiga-
b ca
d e f
Fig. 2. Neuroradiological findings. Fluid-attenuated inverse recovery (FLAIR) MRI of family members III.1 at 31 
years (a–c) and III.2 at 28 years (d–f); coronal planes (with oblique “temporal angulation” in the upper row). 
Whereas there is no marked mesiotemporal atrophy, both examinations show cortical atrophy in bilateral pari-

























   
   
   
   
   
























tions have consistently demonstrated that it results in a 
marked, approximately threefold increase in Aβ42 pro-
duction [43, 51, 52] and, with variations across publica-
tions due to methodological differences, an elevated Aβ42/
Aβ40 ratio as well [51]. It should be noted that these results 
were obtained from in vitro investigations or animal 
studies so that it remains to be determined how they re-
late to the measurement of Aβ CSF levels in patients.
As for PSEN1 mutations in general it remains undeter-
mined whether other genetic or environmental factors 
might contribute to the high neurotoxicity of the S170F 
mutation. The apolipoprotein E allele, for instance, was 
analysed in 3 patients, who were homozygous for the 
“neutral” type (E3/E3). Furthermore, Ehling et al. [45] 
reported 3 patients where the S170F mutation co-segre-
gated with a variant of the cathepsin D gene. The rele-
vance of this finding remains unclear, considering that all 
patients inherited the cathepsin D variant from their (un-
affected) father.
Phenotypic Variability of the PSEN1 S170F Mutation
Atypical phenotypes of PSEN1 mutations are typically 
characterized by cognitive symptoms beyond episodic 
memory impairment typically characterizing the onset of 
sporadic AD as well as frequent non-cognitive (e.g., mo-
tor) symptoms. This greater variability of clinical findings 
might be associated with stronger white matter involve-
ment and more widespread cortical atrophy in PSEN1 
Table 2. Clinical findings in the published S170F cases
Snider et al. [44], 
2005
Golan et al. [41], 
2007
Piccini et al. [43], 
2007
Langheinrich et al. [42], 
2011
Ehling et al. [45], 
2013
Tiedt et al. 
(this study)




3 (2) 1 (de novo) 1 (incomplete family 
history)






II.1:  27 (†37)
III.1: 27 (†35)
III.3: 26 (†43)1






I.1: around 20s (†36)
II.1: around 30 (†32)
III.1: 28 (+6 years)





































MRI: cortical atrophy 
in the parietal and 
temporal lobes
MRI: generalized cerebral 
and cerebellar atrophy, 
increased signal from both 
hippocampi and amygdalae
MRI: parietal/global 
cortical atrophy (3/3), 
FLAIR hyperintensities in 
bilateral mesial temporal 
lobe (1/3)
MRI: cortical atrophy 
of the parietal lobes 
(2/2)
CT: generalized brain 
atrophy (1)
SPECT/PET n.a. Hypoperfusion in 





n.a. Bilateral temporal (1/2) 
and parietal (2/2) 
hypometabolism
n.a.
EEG n.a. “Disorganized basic 
rhythm, disengaged 
theta and delta waves, 
mainly generalized”
Bilateral parietal 
slowing (5/s theta 
waves)
Bilateral temporal slowing, 




delta rhythm (2/2); 
intercurrent spikes 
and sharp waves (1/2)























AD pathology, no 
α-synuclein pathology 
(frontal lobe biopsy)
AD pathology including 
cerebellum, no α-synuclein 
pathology (1)
n.a.
Most examinations were only available in a limited number of cases, and findings were heterogeneous, therefore the proportion of a given result with respect to the overall number 
of available examinations is indicated in parentheses. If only “late twenties” or “early thirties” could be specified as age at onset or death, estimated values are indicated by ”around.” For 
5 patients, the last follow-up status relative to disease onset is reported. Memory loss was present in all cases and is therefore not noted under clinical signs and symptoms. Standard CSF 
parameters (cell count, protein, glucose, and lactate) were reported as normal when available. Aβ refers to Aβ42. n.a., not available. 1 In these patients, the apolipoprotein ε allele was 

























   
   
   
   
   






















mutations [53]. Moreover, it has recently been proposed 
that, aside from altered processing of Aβ species being the 
common denominator of familial AD [10], various other 
γ-secretase substrates may also contribute to atypical 
phenotypes associated with PSEN1 mutations [31]. In the 
following we will review clinical findings associated with 
the S170F mutation in the context of phenotypic variabil-
ity alongside possible clinicopathological correlations 
and findings yielded by standard diagnostic procedures 
in these patients.
Non-Amnestic Cognitive Symptoms
All observed S170F patients had initial memory symp-
toms with frequent and variable non-amnestic cognitive 
symptoms. Due to different neuropsychological testing 
procedures performed at onset or later stages of disease, 
however, phenotypic variability is difficult to determine 
in this regard. Cognitive dysfunction beyond memory 
loss included impaired verbal fluency, attention, and 
apraxia. Furthermore, visuoconstruction and visuospa-
tial abilities were affected in contrast (at onset) to rela-
tively intact object and face recognition. Both face and 
object perceptions have been associated with the mainly 
temporal “ventral stream” whereas other visuospatial 
abilities (e.g., mental rotation) involve the parietal “dorsal 
stream” [for reviews on this model in the context of neu-
rodegeneration, see 54, 55]. Altogether, the presence of 
noticeable non-amnestic cognitive impairment associat-
ed with the S170F mutation corresponds to the literature 
suggesting frequent atypical findings in PSEN1 mutations 
[27–29, 34, 56]. There is, however, some disagreement 
about its exact prevalence in different publications based 
on either reviews and meta-analyses of published cases or 
data from the Dominantly Inherited Alzheimer Disease 
Network (DIAN) study including a larger population of 
patients. There are several possible explanations for these 
differences, such as a variable time of observation and 
thus more or less information about initial versus late 
stages of disease. Furthermore, atypical clinical findings 
might be overestimated in case reports in addition to pos-
sible measurement and ascertainment bias [32]. In a re-
cent investigation the prevalence of aphasia (57.9 vs. 
23.0%), visual agnosia (55.1 vs. 5.6%), and behavioural 
changes (61.7 vs. 31.7%) was indeed significantly higher 
in DIAN patients than in published case reports [32]. 
Moreover, Ryan et al. [31] reported atypical cognitive 
findings in addition to amnesia in 16% of PSEN1 muta-
tions based on a large case series. Although non-amnestic 
presentations are more frequent in familial than sporadic 
AD cases, a comparison of cognitive profiles does not dis-
tinguish both groups [25, 57]. Generally, non-amnestic 
cognitive symptoms at disease onset are more common 
in younger AD patients [58, 59].
Non-Cognitive Symptoms
The most frequently observed non-cognitive symp-
toms in the S170F cases were motor abnormalities includ-
ing cerebellar ataxia, pyramidal signs, myoclonus, and 
seizures. Most often (in 73% of all cases) a combination 
of cerebellar signs, including insecure gait with limb and 
trunk ataxia as well as intention tremor, dysmetria, dys-
diadochokinesia, poor coordination, and saccadic pur-
suit, was noted. Nevertheless, there were also single pa-
tients presenting with purely amnestic [44] or predomi-
nantly neuropsychiatric and parkinsonian features [41]. 
Similarly, seizures occurred in several patients in late 
stages of the disease, but (along with myoclonus) were 
absent in the Austrian family reported by Ehling et al. 
[45]. Apparently, an ataxic variant is the most frequent, 
but not specific clinical phenotype of the S170F mutation. 
There is not enough available evidence to suspect anoth-
er clinical subtype associated with the S170F mutation 
(e.g., ataxia and myoclonus vs. parkinsonism and delu-
sions) as for instance 4 possible clinical presentations of 
the M146L mutation [36].
When comparing the most frequent non-cognitive 
symptoms to their prevalence in larger groups of EOFAD 
patients, the results again vary between the DIAN obser-
vational study and the literature with respect to myoclo-
nus (9.3 vs. 19.4%), seizures (2.8 vs. 20.3%), and ataxia (15 
vs. 3.1%). Worth noting, the prevalence of cerebellar atax-
ia was much higher in PSEN1 mutations located before 
codon 200, in younger patients and those with severer 
symptoms [32]. In this context, the presence of distinctive 
cerebellar signs in the majority of S170F patients corre-
sponds to other PSEN1 precodon 200 mutations with a 
very early onset and a marked “cerebellar” phenotype as 
for instance the P117A [60], N135S [61], M139V [62], 
T147P [63], H163P [64], L166P [65], and S169L muta-
tions [66]. In the case series reported by Ryan et al. [31], 
myoclonus was present in 47%, seizures in 24%, and py-
ramidal signs in 25% of PSEN1 mutation carriers. The 
occurrence of myoclonus increased the risk of later sei-
zures. As to cerebellar ataxia, this was only noted in 4% of 
all PSEN1 patients.
Clinicopathological Correlations
To what extent are these clinical symptoms correlated 
with neuropathological findings? First, the available neu-

























   
   
   
   
   
























frontal lobe biopsy) describe characteristic AD pathology 
with amyloid plaques and neurofibrillary tangles. In ad-
dition, Lewy bodies were found in 1 case [44] but absent 
in another 3 patients where neuropathological examina-
tions included staining for Lewy bodies using monoclo-
nal antibodies against α-synuclein [42, 43, 45]. A clinical 
phenotype resembling Lewy body dementia with parkin-
sonism and delusional symptoms was observed in al-
together 2 patients [41, 44]. It should be noted that 
α-synuclein pathology is, alongside other atypical find-
ings and with considerable variability, described relative-
ly often in familial AD cases [21, 67]. Consistent with fre-
quent cerebellar symptoms, abundant amyloid deposits 
in the cerebellum and loss of Purkinje cells was described 
in 2 patients [43, 45]. However, in contrast to its relative-
ly rare clinical manifestations, cerebellar pathology is 
consistently described in both sporadic [68–72] and fa-
milial AD cases [35, 67, 73–75]. Cerebellar damage is 
thought to characterize a late event in the sequence of 
amyloid deposition in distinct brain regions [76]. Consid-
ering the high pathogenicity of the S170F mutation this 
may resemble a “quick motion” picture of AD pathology.
Diagnostic Procedures
The diagnostic procedures conducted in the patients 
yielded several results indicating AD pathology that 
helped to establish the diagnosis in the end. Before ge-
netic testing, a variety of suspected differential diagnoses 
were investigated in the reported S170F cases including 
Wilson’s disease, prion disease (CJD/vCJD), hereditary 
spinocerebellar ataxia and infectious or auto-immune en-
cephalitis. The latter was suspected in 2 S170F due to T2-
weighted and fluid-attenuated inverse recovery (FLAIR) 
hyperintensities of the medial temporal lobes. Similar 
MRI findings including white matter abnormalities asso-
ciated with T2-weighted/FLAIR hyperintensities have 
been observed previously in several other PSEN1 muta-
tions [77–79] and might reflect cerebral amyloid angi-
opathy, which, however, was found to be severest in post-
codon 200 PSEN1 mutations [80]. Furthermore, struc-
tural imaging (MRI was available in overall 8 cases) most 
consistently showed cortical atrophy accentuated in pari-
etal areas alongside generalized and temporal atrophy, 
paralleled by hypoperfusion or -metabolism in these ar-
eas using functional imaging techniques (in 4 patients). 
This pattern of cortical atrophy may correspond to the 
more pronounced deterioration of cognitive abilities as-
sociated with the dorsal visual stream in several S170F 
patients. A similar correlation of the topography of corti-
cal atrophy and neuropsychological profile was suggested 
in early-onset AD patients in contrast to late-onset AD 
patients where mesiotemporal and hippocampal atrophy 
were the most consistent findings [81]. A pattern of tem-
poroparietal cortical atrophy was also linked to the be-
havioural and dysexecutive variant of sporadic AD [82].
CSF biomarkers (available in 4 patients) included re-
duced Aβ42 and increased t-tau and p-tau protein, remi-
niscent of sporadic AD [83]. This is in line with recent 
investigations of larger populations suggesting that 
changes of CSF biomarkers are comparable in familial 
and sporadic AD [13, 34, 84]. Similarly, EEG alterations 
including general or regional slowing over temporal and 
parietal areas and epileptiform activity in particular in 
several of the S170F cases are frequently observed in both 
sporadic and familial AD with epileptic seizures [85, 86].
Conclusions
In conclusion, the findings in our patients and in pre-
viously published cases suggest that very early onset in the 
late twenties and initial memory impairment are consis-
tently found in S170F patients whereas non-amnestic 
cognitive and non-cognitive symptoms were common 
but also variable. A combination of widespread cognitive 
impairment with myoclonus and/or cerebellar ataxia was 
most frequently observed. As there was considerable in-
terindividual phenotypic variability, the question of an-
other subtype with symptoms resembling Lewy body de-
mentia remains unresolved. Furthermore, the observa-
tion of visuospatial impairment with less affected face and 
object recognition at initial stages in the sense of a disso-
ciation between cognition related to the ventral and dor-
sal stream needs confirmation in further investigations. 
Finally, the findings in S170F patients highlight the rele-
vance of obtaining detailed clinical phenotypes, since de-
termining genotype-phenotype associations is mostly 
limited by scarce or heterogeneous information available 
from previous case reports. Moreover, variable and atyp-
ical clinical presentation of PSEN1 mutations also repre-
sents a special diagnostic challenge [40], and the exami-
nation of CSF Aβ species may be particularly important 
to indicate the underlying AD pathology.
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